Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBelluscura Regulatory News (BELL)

Share Price Information for Belluscura (BELL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.75
Bid: 7.00
Ask: 8.50
Change: 0.00 (0.00%)
Spread: 1.50 (21.429%)
Open: 7.75
High: 7.75
Low: 7.75
Prev. Close: 7.75
BELL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Distribution Agreement & New VP North America

13 Feb 2024 07:00

RNS Number : 8870C
Belluscura PLC
13 February 2024
 

13 February 2024

 

Belluscura plc

("Belluscura" or the "Company")

 

Belluscura announces implementation of distribution agreement with Sunset HealthCare Solutions

New Vice President of North American Sales

 

Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces a new partnership with Sunset HealthCare Solutions ("Sunset Healthcare") and the promotion of Konstantin Grey to Vice President of North American Sales.

 

Sunset HealthCare is a Chicago-based manufacturer and distributor of Home Medical Equipment ("HME") supplies offering an extensive range of quality HME products, innovative solutions and specialised product support. It partners with over 1,600 healthcare businesses, serving all of the United States alongside key international accounts. Sunset Healthcare has a network of sales representatives extending across the US and in 150 countries around the globe.

 

Under the distribution agreement, Sunset HealthCare will offer the X-PLOR® portable oxygen concentrator ("POC") to over 1,600 customers. It is intended that the agreement will be extended to also include distribution of the award winning DISCOV-R? POC in Q2 2024 when the product becomes available to Durable Medical Equipment ("DME") suppliers.

 

Belluscura also announces that Konstantin Grey has been appointed Vice President of North American Sales. Having joined Belluscura in July 2023, Konstantin has been responsible for the creation and launch of Belluscura's direct to consumer sales force and website, which has seen strong growth in sales and gross margins since its launch last year. He also successfully launched our unique direct to consumer leasing program and has been instrumental in driving this new partnership with Sunset HealthCare, as well as a healthy pipeline of further opportunities. Konstantin has 15 years of experience in the DME industry, including having founded and subsequently sold his own DME company.

 

Robert Rauker, Chief Executive Officer, Belluscura plc, said:

 

"We welcome the new partnership with Sunset HealthCare Solutions, which will provide over 1,600 healthcare businesses with access to our innovative products through a trusted, industry leader. This agreement significantly expands our distribution network."

 

PJ Ruflin, VP Business Development, Sunset Healthcare Solutions, stated:

 

"Sunset Healthcare Solutions is committed to finding great products and partners to support our customers and their patients. Our partnership with Belluscura offers a unique opportunity to bring meaningful innovation and support to the market at a critical time."

 

Bob Fary, Senior Vice President of Global Sales, commented:

 

"Konstantin has been a tremendous asset since joining Belluscura, as demonstrated by his ability to bring on partners like Sunset Healthcare Solutions. In his new role as VP of North America, Konstantin is set to further drive Belluscura's mission of enhancing patient quality of life through innovative, accessible healthcare solutions. We look forward to building on our success to date as we launch our next generation molecular sieve technology and DISCOV-R."

 

END

 

For further information, please contact:

 

Belluscura plc

www.belluscura.com

Robert Rauker, Chief Executive Officer

via MHP

Simon Neicheril, Chief Financial Officer

SPARK Advisory Partners Limited (NOMAD)

Tel: +44 (0)20 3368 3550

Neil Baldwin / Jade Bayat

Dowgate Capital Limited (Broker)

Tel: +44 (0)20 3903 7715

James Serjeant / Nicholas Chambers

MHP Communications (Financial PR and Investor Relations)

Tel: +44 (0)20 3128 8100 / +44 7884 494112

Katie Hunt / Matthew Taylor

Email: belluscura@mhpgroup.com

 

 

About Belluscura plc ( www.belluscura.com )

Belluscura is a UK medical device company focused on developing high performing, lightweight and portable oxygen enrichment technology used in a broad range of industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health, mobility and economic outcomes for patients, healthcare providers and insurance organisations.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGREAEAAFDKLEAA
Date   Source Headline
17th Apr 20247:00 amRNSBelluscura Concert Party
11th Apr 202410:23 amRNSHolding(s) in Company
8th Apr 20241:15 pmRNSHolding(s) in Company
5th Apr 20243:48 pmRNSIssue of Equity
2nd Apr 20247:00 amRNSTrading Update
28th Mar 20247:00 amRNSTotal Voting Rights
8th Mar 20244:36 pmRNSOffer Closed
7th Mar 20248:30 amRNSCancellation of Listing and trading
4th Mar 20247:00 amRNSAcceptances level
26th Feb 20247:00 amRNSAcceptances level
22nd Feb 20243:00 pmRNSAcceptances level, issue of equity & AIM Admission
19th Feb 20247:00 amRNSAcceptances level & offer closing
15th Feb 20243:51 pmRNSAcceptances level, issue of equity & AIM Admission
13th Feb 20247:00 amRNSDistribution Agreement & New VP North America
13th Feb 20247:00 amRNSAcceptances Level
12th Feb 20241:44 pmGNWForm 8.3 - Belluscura PLC
9th Feb 20248:16 amRNSOffer becomes wholly unconditional
8th Feb 20243:31 pmRNSAcceptances level, issue of equity & AIM Admission
7th Feb 20244:20 pmRNSOffer Unconditional (subject to AIM Admission)
7th Feb 202411:13 amRNSForm 8.3 - Belluscura Plc
5th Feb 20241:30 pmRNSResult of General Meeting
5th Feb 20247:00 amRNSAcceptances received in respect of the Offer
2nd Feb 202411:24 amRNSForm 8 (OPD) Belluscura plc
2nd Feb 202411:18 amRNSForm 8 (OPD) TMT Acquisition plc
1st Feb 20246:16 pmRNSForm 8 (OPD) TMT Acquisition plc - Amended
1st Feb 20246:14 pmRNSForm 8 (OPD) Belluscura plc - Amended
1st Feb 20242:34 pmGNWForm 8.3 - Belluscura PLC
29th Jan 202411:42 amRNSForm 8.3 - Belluscura PLC
24th Jan 20246:24 pmRNSForm 8.3 - Belluscura PLC
24th Jan 20246:17 pmRNSForm 8.3 - Belluscura
24th Jan 20246:02 pmRNSForm 8.3 - Belluscura PLC - Replacement
24th Jan 20245:49 pmRNSForm 8.3 - Belluscura PLC
24th Jan 20243:25 pmRNSForm 8.3 - Belluscura plc
24th Jan 20243:14 pmRNSHolding(s) in Company
24th Jan 202410:45 amRNSForm 8.3 - Belluscura Plc
23rd Jan 20246:06 pmRNSForm 8.3 - Belluscura plc
23rd Jan 20245:39 pmRNSForm 8.3 - BELLUSCURA PLC
19th Jan 20241:30 pmRNSPosting of Offer Document and Circular
8th Jan 20241:01 pmGNWForm 8.3 - Belluscura PLC
22nd Dec 202312:10 pmRNSExtension to deadline for posting Offer Document
20th Dec 20237:00 amRNSChinese registration and Trading Update
19th Dec 20231:04 pmGNWForm 8.3 - Belluscura PLC
13th Dec 20232:43 pmGNWForm 8.3 - Belluscura PLC
12th Dec 20237:00 amRNSBelluscura Receives Approval in Singapore
28th Nov 20235:00 pmRNSExtension to deadline for posting Offer Document
24th Nov 20232:06 pmGNWForm 8.3 - Belluscura PLC
16th Nov 202312:20 pmRNSForm 8.3 - Belluscura PLC
16th Nov 202312:12 pmRNSForm 8.3 - Belluscura PLC
9th Nov 202311:04 amRNSForm 8.3 - TMT Acquisition PLC
8th Nov 20235:52 pmRNSForm 8.3 - TMT Acquisition plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.